Literature DB >> 6800300

[Production of monoclonal antibodies against HBs (author's transl)].

J Kalil, D Crevat, M Fellous, J Drouet, A M Courouce, C Ropars.   

Abstract

Two BALB/c mice were immunized 4 times with a mixture of adw2 and ayw4 subtypes of HBs antigens. Their spleens were then hybridized with mouse myeloma cell line NS1. Using three different radioimmunoassays (RIA), 264 independent hybridomas were screened for anti-HBs activity. By at last one of these techniques, 95% of the colonies were positive. Selected colonies were cloned and supernatants studied by RIA and immunodiffusion techniques for specificity characterisation. Some clones recognised the common "a" subtype, and other were directed to more restricted specificities. Ascites fluid was active on RIA up to 10(7) dilution (up to 29.000 UI/ml). These monoclonal antibodies may be powerful reagent for the diagnosis and understanding of viral hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6800300

Source DB:  PubMed          Journal:  Ann Immunol (Paris)        ISSN: 0300-4910


  2 in total

1.  Rheumatic heart disease: proinflammatory cytokines play a role in the progression and maintenance of valvular lesions.

Authors:  Luiza Guilherme; Patricia Cury; Lea M F Demarchi; Verônica Coelho; Lúcia Abel; Ana P Lopez; Sandra Emiko Oshiro; Selma Aliotti; Edécio Cunha-Neto; Pablo M A Pomerantzeff; Ana C Tanaka; Jorge Kalil
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

2.  In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals.

Authors:  Leo Kei Iwai; Márcia Yoshida; John Sidney; Maria Aparecida Shikanai-Yasuda; Anna Carla Goldberg; Maria Aparecida Juliano; Jurgen Hammer; Luiz Juliano; Alessandro Sette; Jorge Kalil; Luiz Rodolpho Travassos; Edecio Cunha-Neto
Journal:  Mol Med       Date:  2003 Sep-Dec       Impact factor: 6.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.